Genprex Secures $6.5 Million in Funding Through Registered Direct Offering
Genprex, a leading gene therapy company, recently announced the closing of a $6.5 million registered direct offering priced at-the-market under Nasdaq rules.This funding will allow the company to further advance its clinical-stage therapies for patients with cancer and diabetes.With 57.805639 million shares outstanding and a current stock price of $3.02, this news is expected to have a significant impact on the company’s shares and overall market position.
Comments